Pattern-reversal visual evoked potentials in patients with human T-lymphotropic virus type 1 uveitis

Current Eye Research

Volumn 31, Issue 1, 2006, Pages 37-42

  Yukawa, Eiichi ^a,b   Urano, Toru ^a   Nakahara, Masaaki ^a   Miyata, Kazunori ^a   Matsuura, Toyoaki ^b   Taketani, Futoshi ^b   Hara, Yoshiaki ^b   Mochizuki, Manabu ^c  

^a Miyata Eye Hospital   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

HTLV 1 uveitis; P100 peak latency; Pattern reversal visual evoked potentials; Vogt Koyanagi Harada disease

Indexed keywords

HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; AGGLUTINATION TEST; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; EYE INJURY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LATENT PERIOD; MALE; MEASUREMENT; PATIENT; PRIORITY JOURNAL; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM; VOGT KOYANAGI SYNDROME;

ADOLESCENT; ADULT; AGED; EVOKED POTENTIALS, VISUAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MIDDLE AGED; REACTION TIME; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 31544475977     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500479509     Document Type: Article

References (25)

1. Tajima K. The T and B cell Malignancy Study Group. The 4th nationwide study of adult T cell leukaemia/lymphoma(ATL) in Japan. Int J Cancer. 1990;45:237-243.
2. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534-2537.
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to the human T-lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet. 1985;ii:407-410.
4. Osame M, Usuku K, Izumo S, et al. HTLV- I associated myelopathy, A new clinical entity. Lancet. 1986;i:1031-1032.
5. Nishioka K, Maruyama I, Sato K, et al. Chronic inflammatory arthropathy associated with HTLV- I. Lancet. 1989;i:441.
6. Ohshima K, Kikuchi M, Masuda Y, et al. HTLV- I associated lymphadenitis. Cancer. 1992;69:239-248.
7. Ohba N, Matsumoto M, Sameshima M, et al. Ocular manifestations in patients infected with human T-lymphotropic virus type I. Jpn J Ophthalmol. 1989;33:1-12.
8. Nakao K, Matsumoto M, Ohba N. Seroplevalence of antibodies to HTLV-I in patients with ocular disorders. Br J Ophthalmol. 1991;75:76-78.
9. Araki S, Mochizuki M, Yamaguchi K, et al. Familial clustering of human T-lymphotropic virus type 1 uveitis. Br J Ophthalmol. 1993;77:747-748.
10. Mochizuki M, Tajima K, Watanabe T, Yamaguchi K. Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol. 1994;78:149-154.
11. Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, et al. HTLV-1 uveitis: a distinct clinical entity caused by HTLV- I. Jpn J Cancer Res. 1992;83:236-239.
12. Mochizuki M, Watanabe T, Yamaguchi K, et al. Uveitis associated with human T lymphotropic virus type I: seroepidemiological, clinical, and virological studies. J Infect Dis. 1992;166:943-944.
13. Ono A, Mochizuki M, Yamaguchi K, et al. Increased number of circulating HTLV- 1 infected cells in peripheral blood mononuclear cells of HTLV- 1 uveitis patients: a quantitative polymerase chain reaction study. Br J Ophthalmol. 1995;79:270-276.
14. Yamaguchi K, Mochizuki M, Watanabe T, et al. Human T-lymphotropic virus type 1 uveitis after Graves' disease. Br J Ophthalmol. 1994;78:163-166.
15. Yoshimura K, Mochizuki M, Araki S, et al. Clinical and immunological features of human T-cell lymphotropic virus type I uveitis. Am J Ophthalmol. 1993;116:156-163.
16. Arimura Y, Arimura K, Osame M, Igata A. Neuro-ophthalmological abnormalities in HTLV- I associated myelopathy. Neuro-ophthalmology. 1987;7:243-248.
17. Kakigi R, Shibasaki H, Kuroda Y, et al. Multimodality evoked potentials in HTLV- I associated myelopathy. J. Neurol Neurosurg Psychiatry. 1988;51:1094-1096.
18. Lennerstrand G. Delayed visual evoked cortical potencials in retinal disease. Acta Ophthalmol. 1982;60:497-504.
19. Papakostopoulos D, Hart CD, Cooper R, Natsikos V. Combined electrophysiological assessment of the visual system in central serous retinopathy. Electroencephalogr Clin Neurophysiol. 1984;59:77-80.
20. Folk JC, Thompson HS, Han DP, Brown CK. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. 1984;102:1299-1302.
21. Bass SJ, Sherman J, Bodis-Wollner I, Nath S. Visual evoked potentials in macular disease. Invest Ophthalmol Vis Sci. 1985;26:1071-1074.
22. Junghardt A, Wildberger H, Török B. Pattern electroretinogram, visual evoked potential and psychophysical functions in maculopathy. Doc Ophthalmol. 1995;90:229-245.
23. Negishi C, Takasoh M, Fujimoto N, et al. Visual evoked potentials in relation to visual acuity in macular disease. Acta Ophthlmol Scand. 2001;79:271-276.
24. Salahuddin SZ, Markham PD, Lindner SG, et al. Lymphokine production by cultured human R cells transformed by human T-cell leukemia-lymphoma virus-I. Science. 1984;223:703-707.
25. Ono A, Ikeda E, Mochizuki M, et al. Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities. Jpn J Cancer Res. 1998;89:608-614.